Emerging Infectious Diseases (May 2017)

Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China

  • Fuqiang Cui,
  • Lipin Shen,
  • Li Li,
  • Huaqing Wang,
  • Fuzhen Wang,
  • Shengli Bi,
  • Jianhua Liu,
  • Guomin Zhang,
  • Zijian Feng,
  • Hui Zheng,
  • Xiaojin Sun,
  • Ning Miao,
  • Zundong Yin

DOI
https://doi.org/10.3201/eid2305.161477
Journal volume & issue
Vol. 23, no. 5
pp. 765 – 772

Abstract

Read online

China’s hepatitis B virus (HBV) prevention policy has been evaluated through nationally representative serologic surveys conducted in 1992 and 2006. We report results of a 2014 serologic survey and reanalysis of the 1992 and 2006 surveys in the context of program policy. The 2014 survey used a 2-stage sample strategy in which townships were selected from 160 longstanding, nationally representative, county-level disease surveillance points, and persons 1–29 years of age were invited to participate. The 2014 sample size was 31,713; the response rate was 83.3%. Compared with the 1992 pre–recombinant vaccine survey, HBV surface antigen prevalence declined 46% by 2006 and by 52% by 2014. Among children <5 years of age, the decline was 97%. China’s HBV prevention program, targeted toward interrupting perinatal transmission, has been highly successful and increasingly effective. However, this progress must be sustained for decades to come, and elimination of HBV transmission will require augmented strategies.

Keywords